Mayukh Sukhatme sold $24M of ROIV
President & CIO at Roivant Sciences Ltd.. 664,826 shares at an average of $36.34, traded Aug 14, 2026, filed Aug 18, 2026.
Score components
- +20RolePresident
- +25Trade size$24.2M at market
- 0Share of holdings soldSold 3.5% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001140361-26-033637, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | MOption exercise Common Shares | +243,177 | $3.85 | $936k | 18,873,916 | Aug 18, 2026 |
| Aug 14, 2026 | SOpen-market sale Common Shares | -243,177 | $36.23 | $8.8M | 18,630,739 | Aug 18, 2026 |
| Aug 17, 2026 | MOption exercise Common Shares | +284,707 | $3.85 | $1.1M | 18,915,446 | Aug 18, 2026 |
| Aug 17, 2026 | SOpen-market sale Common Shares | -284,707 | $36.25 | $10M | 18,630,739 | Aug 18, 2026 |
| Aug 18, 2026 | MOption exercise Common Shares | +105,141 | $3.85 | $405k | 18,735,880 | Aug 18, 2026 |
| Aug 18, 2026 | SOpen-market sale Common Shares | -105,141 | $36.59 | $3.8M | 18,630,739 | Aug 18, 2026 |
| Aug 18, 2026 | MOption exercise Common Shares | +31,801 | $3.85 | $122k | 18,662,540 | Aug 18, 2026 |
| Aug 18, 2026 | SOpen-market sale Common Shares | -31,801 | $37.18 | $1.2M | 18,630,739 | Aug 18, 2026 |
| Aug 14, 2026 | MOption exercise Common Sharesderivative | -243,177 | $0.00 | $0 | 13,981,186 | Aug 18, 2026 |
| Aug 17, 2026 | MOption exercise Common Sharesderivative | -284,707 | $0.00 | $0 | 13,696,479 | Aug 18, 2026 |
| Aug 18, 2026 | MOption exercise Common Sharesderivative | -136,942 | $0.00 | $0 | 13,559,537 | Aug 18, 2026 |
Related signals
Other insiders at Roivant Sciences Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $641k 17,750 shares | -54% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.3M 200,000 shares | -11% | |
| 25Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $196k 4,938 shares | -33% | |
| 20Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $203k 5,112 shares | -12% | |
| 27Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $798k 20,000 shares | -32% | |
| 35Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.2M 200,000 shares | -11% | |
| 38Weak | Roivant Sciences Ltd. | Mayukh Sukhatme President & CIO | $12M 335,174 shares | -2% | |
| 20Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.0M 200,000 shares | -11% | |
| 15Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $349k 10,000 shares | -19% | |
| 35Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $610k 17,750 shares | -52% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.